Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPIRED III of RESCAP for prevention of kidney injury and inflammation after cardiac surgery
NL-OMON49105Phase 3Recruiting
- Sponsor
- Alloksys Life Sciences
- Start
- Nov 2017
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute kidney failure (AKF), kidney failure and Systemic Inflammatory Response Syndrome (SIRS) comparing RESCAP with Placebo (2 arms). Primary endpoints: Composite primary outcome, Acute kidney injury or acute renal failure and 3 more. Started Nov 2017; status: recruiting.
02
Drugs
bovine intestinal alkaline phosphatase
03
Conditions
acute kidney failure (AKF)kidney failureSystemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on NL-OMON49105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49105.